Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Dermata Therapeutics Q3 2026 Results: Net Loss of $2.82M, Loss Widens

Dermata Therapeutics transitioned from a prescription R&D focus to a direct-to-consumer skincare brand, launching its first Tome product in August 2026. For the nine months ended September 30, 2026, the company reported a net loss of $7.6 million on initial sales of $74,137, with cash reserves decreasing to approximately $4.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.1—
Gross profit0.0—
Net income-2.8-1.7
EPS (diluted, $ a share)$-0.55$-1.65

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Gross margin54.1%
Source

10-Q filed with the SEC, NASDAQ: DRMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Dermata Therapeutics, Inc.: key numbers

Share price
$0.5985Close, Nov 16
Market cap
$2.95M
Shares outstanding
4.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dermata Therapeutics, Inc.

All →
8:31 AM ET 8-K
Business Update

Dermata Therapeutics Business Update

Dermata Therapeutics released additional results and photos from its recently completed cosmetic clinical study of Tome Foundational Treatment. The company also announced it has received over 1,000 orders for the skin renewal treatment since its recent commercial launch.

4:08 PM ET 8-K
Financial Results

Dermata Therapeutics Financial Results

Dermata Therapeutics reported financial results for the third quarter of 2026, highlighting its transition to a revenue-generating company following the August 2025 launch of Tome Foundational Treatment. The company reported its first product revenue and noted that approximately 30% of orders were generated via subscriptions.

Term
Q3 2026

“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer

“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
5:26 PM ET 8-K
Business Update

Dermata Therapeutics Business Update

Dermata Therapeutics announced the enrollment of the first participant in a clinical trial for Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch this product commercially in the first half of 2027 as part of its strategic shift toward skincare products.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.